Sunshine Biopharma, Inc. (NASDAQ:SBFM) Stock Short Interest Rises 461.6%

Sunshine Biopharma, Inc. (NASDAQ:SBFM) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 131,478 shares, an increase of 461.6% from the September 15th total of 23,410 shares. Approximately 3.1% of the shares of the company are sold short. Based on an average trading volume of 161,724 shares, the days-to-cover ratio is presently 0.8 days.

Sunshine Biopharma Stock Down 21.4%

Sunshine Biopharma stock opened at $0.34 on Friday. Sunshine Biopharma has a 52-week low of $0.33 and a 52-week high of $24.30. The company has a market cap of $1.46 million, a P/E ratio of -0.03 and a beta of 1.20. The business has a 50-day simple moving average of $1.01 and a two-hundred day simple moving average of $3.89.

Sunshine Biopharma (NASDAQ:SBFM) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($1.20) by $0.05. The firm had revenue of $9.26 million for the quarter, compared to analysts’ expectations of $8.70 million. Sunshine Biopharma had a negative net margin of 17.94% and a negative return on equity of 26.36%. Research analysts anticipate that Sunshine Biopharma will post -1.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SBFM has been the subject of several research reports. Wall Street Zen raised shares of Sunshine Biopharma to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings upgraded shares of Sunshine Biopharma from a “sell (e)” rating to a “sell (e+)” rating in a research note on Thursday, September 24th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a pharmaceutical and biotechnology company focused on developing and commercializing therapies for cancer and other medical conditions. The company’s research pipeline has included Adva-27a, an anticancer compound designed to target tumors that may be resistant to existing treatments, as well as mRNA-based therapeutic candidates.

Through its Canadian operations, including Nora Pharma, Sunshine Biopharma is also involved in the development, marketing and distribution of prescription and over-the-counter pharmaceutical products.